Funding for this research was provided by:
Signe ja Ane Gyllenbergin Säätiö
Received: 23 April 2020
Accepted: 25 January 2021
First Online: 14 February 2021
Ethics approval and consent to participate
: All subjects provided written consent. The study protocol was approved by the Ethics Committee of the Helsinki and Uusimaa Hospital District and it was registered in ClinicalTrials.gov (NCT03300635).
: Not applicable.
: Eija Kalso has served on the advisory boards of Orion Pharma and Pfizer. The other authors have no conflicts of interest to declare.